Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
FAQ
Apa simbol saham E-Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa Boerse Stuttgart, saham E-Therapeutics diperdagangkan dengan simbol 3AQ.STU.
Berapa jumlah karyawan E-Therapeutics?▼
Per 2 November 2026, perusahaan memiliki 34 karyawan.
E-Therapeutics berada di sektor apa?▼
E-Therapeutics beroperasi di sektor Kesehatan & Kebugaran.
Kapan E-Therapeutics menyelesaikan split saham?▼
E-Therapeutics belum melakukan split saham baru-baru ini.
Di mana kantor pusat E-Therapeutics?▼
Kantor pusat E-Therapeutics berlokasi di London, Britania Raya.